Results 141 to 150 of about 69,340 (246)

How Far Can we Go? Managing Moyamoya Syndrome in a 3‐Year‐Old With Thalassemia Major: A Rare Pediatric Case From Nepal

open access: yesClinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Moyamoya syndrome (MMS) is a rare progressive cerebrovascular disorder causing stenosis of intracranial arteries and collateral vessel formation. Pediatric presentations often include ischemic strokes, and coexisting Thalassemia Major may worsen vascular outcomes.
Kshitiz Parajuli   +8 more
wiley   +1 more source

Non‐Specific Interstitial Pneumonia in Anti‐Jo1 Synthetase Syndrome With Probable Gougerot Syndrome: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Anti‐synthetase syndrome (ASS) is a rare autoimmune disorder of idiopathic inflammatory myopathy spectrum, characterized by the presence of aminoacyl‐tRNA synthetase antibodies, most commonly anti‐Jo‐1. Clinically presents with interstitial lung disease (ILD), myositis, and arthritis, and may be confused with other autoimmune conditions such ...
Ali Gohar   +7 more
wiley   +1 more source

Cutaneous Leishmaniasis in High‐Altitude: A Case Report From Nepal

open access: yesClinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Leishmaniasis is a parasitic infection caused by Leishmania and spread by the bite of a sandfly, most commonly Phlebotomus. Among the three subtypes of Leishmaniasis, cutaneous leishmaniasis is the most common form. Visceral Leishmaniasis is common in Nepal whereas few cases of cutaneous leishmaniasis have been reported in migrant Nepalese ...
Eliz Aryal   +5 more
wiley   +1 more source

Secondary Budd-Chiari Syndrome due to Hepatic Tuberculosis in a Pediatric Patient Managed by Left Hepatic Vein Stenting. [PDF]

open access: yesJ Clin Exp Hepatol, 2023
Patel RK   +5 more
europepmc   +1 more source

From Tumor Marker to Congestion Indicator: The Expanding Role of CA‐125 in Heart Failure and Beyond

open access: yesHealth Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims To evaluate the transition of Carbohydrate antigen 125 (CA‐125) from an ovarian tumor marker to a versatile indicator of systemic congestion and fluid overload. Methods A literature review (1984–2025) was conducted using PubMed, Scopus, and Web of Science. Keywords included “CA‐125,” “systemic congestion,” and related terms.
Minoo Heidari Almasi   +4 more
wiley   +1 more source

Machine Learning Based Diagnostic Models for Hip and Knee Prosthetic Joint Infection: A Systematic Review

open access: yesJournal of Orthopaedic Research, Volume 44, Issue 3, March 2026.
ABSTRACT Prosthetic joint infection (PJI) is a devastating complication that affects up to 1.7% of patients within 2 years following total hip arthroplasty (THA) or total knee arthroplasty (TKA). PJI is associated with significant patient morbidity, reduction in quality of life, prolonged hospitalisation, and healthcare expenditure.
Jaiden Nairne‐Nagy   +4 more
wiley   +1 more source

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

open access: yesJEADV Clinical Practice, Volume 5, Issue 1, Page 101-116, March 2026.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson   +12 more
wiley   +1 more source

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

open access: yesMedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy